Metsera (MTSR.US), a company focused on developing weight loss drugs, has filed for an initial public offering (IPO) in the United States, aiming to raise $100 million.

Metsera, a clinical-stage biopharmaceutical company focused on the treatment of obesity and metabolic diseases, filed for an initial public offering (IPO) with the U.S. Securities and Exchange Commission (SEC) on Friday, seeking to raise $100 million. The company plans to list on the Nasdaq under the ticker "MTSR". Metsera is a clinical-stage biopharmaceutical company focused on the treatment of obesity and metabolic diseases. The company is developing next-generation injectable and oral Nutritional Stimulatory Hormones (NuSH) mimetic peptides to treat obesity, overweight, and related diseases. The company's current lead candidate is MET-097, a long-acting subcutaneous GLP-1 receptor agonist currently in development. MET-097 was developed through Metsera's proprietary HALO peptide lipidation platform, which has an extended in vivo clearance time. Data released in September last year showed that MET-097 achieved significant and sustained weight loss in a Phase 1 clinical trial. Weight loss of 7.5% was observed in the trial participants after 36 days of treatment, and its pharmacokinetic profile supports a potential once-monthly dosing regimen. Metsera has initiated a Phase 2b clinical trial for MET-097 in the fourth quarter of 2024, and it is expected to receive preliminary data in the first half of 2025.